Biojiva LLC
4 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
6
Ending by 2030
Mar 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Apr 10, 2027The maintenance fee for Processes for Isotopic Modification of Polyunsaturated Fatty Acids and Derivatives Thereof (US 11,779,910) comes due Apr 10, 2027. Unpaid by Oct 12, 2027, it lapses early.
- 1 fee due Sep 3, 2027The maintenance fee for Site-specific isotopic labeling of 1,4-diene systems (US 10,577,304) comes due Sep 3, 2027. Unpaid by Mar 3, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,320,289 | Isotopically Modified Compounds and Their Use as Food Supplements In force · High confidence | In force | High confidence | |
| US 9,616,042 | Isotopically Modified Compounds and Their Use as Food Supplements In force · High confidence | In force | High confidence | |
| US 10,015,979 | Isotopically Modified Compounds and Their Use as Food Supplements In force · High confidence | In force | High confidence | |
| US 10,918,126 | Isotopically Modified Compounds and Their Use as Food Supplements In force · High confidence | In force | High confidence | |
| US 8,637,486 | Therapeutic substances that modulate genome methylation In force · From the USPTO record | In force | From the USPTO record | |
| US 8,906,405 | Isotopically Modified Compounds and Their Use as Food Supplements In force · High confidence | In force | High confidence | |
| US 10,058,522 | Oxidative Retinal Diseases In force · High confidence | In force | High confidence | |
| US 10,058,612 | Impaired energy processing disorders and mitochondrial deficiency In force · From the USPTO record | In force | From the USPTO record | |
| US 10,154,978 | Disorders implicating PUFA oxidation In force · From the USPTO record | In force | From the USPTO record | |
| US 10,154,983 | Neurodegenerative disorders and muscle diseases implicating PUFAs In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 26: 4 patents in force now held by others · 1 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
7 pending · 1 abandoned · 8 no status recorded